Middle-aged people who exercise more are less likely to become amyloid-positive. In late life, people with brain amyloid who exercise declined more slowly and had less brain shrinkage over the following years.
Longitudinal data identifies four stages of amyloid plaque buildup, with the earliest deposits appearing in the precuneus and posterior cingulate.
New PET Staging Scheme for Amyloid? Physical Activity May Shield the Brain from the Onslaught of Aβ Crenezumab Update: Baseline Data from Colombian Prevention Trial Colombian Cohort Delivers Data on Blood NfL Rare Luck: Two Copies of ApoE2 Shield Against ...
The field is searching for a combination of clinical features and biomarkers that will identify the disease in people with mild cognitive impairment.
The field is rapidly building the infrastructure for biomarker studies and large clinical trials.
A U.K. research program developed guidelines for clinical practice. In preliminary studies, it boosted diagnosis and improved patient care.
New Tool Kit Helps Physicians Recognize and Manage Lewy Body Dementias Consortia Assemble Worldwide to Take on Lewy Body Dementia Dementia with Lewy bodies is a devastating disorder, combining some of the worst features of Alzheimer’s and Parkinson’s, but ...
Using an array of receptors to sense neurons in peril, microglia make matters worse by taking bites out of the struggling cells.
Much of the neuron loss in rTg4510 mice comes from accidental disruptions in mouse genes rather than expression of mutant tau. Pathology spreads quickly in human tau knock-ins.
Going Viral: Alzheimer’s Research at Herpes Conference Herpesvirus: Trigger for Many Brain Pathologies? In light of recent work implicating human herpesviruses in AD, virologists invited Alzheimer’s researchers to join them at the 11th International ...
At Quebec conference, researchers considered multiple aspects of herpesvirus biology that may come in to play in AD.
Injecting α-synuclein fibrils into mouse gut sparked the proteopathic spread of misfolded α-synuclein into the brain, where the aggregates killed dopaminergic neurons and caused motor problems.
Co-sponsors Banner, Novartis, and Amgen announced that they will stop testing CNP520 in two Phase 2/3 studies in people at risk of AD. The drug worsened cognition.
At Quebec conference, human herpesvirus experts devoted a day to consider whether their favorite villain might play a hand in Alzheimer’s pathogenesis.
TREM2 required for reduction of plaque load in CD33 knockouts.